Post by Waters Corporation

Redosing remains one of gene therapy’s toughest challenges, and AAV immunogenicity is a key reason why. A recent Nature Communications study demonstrates how rational AAV capsid engineering can reduce CD4⁺ T‑cell recognition without sacrificing vector function. By integrating computational epitope prediction with experimental validation, the authors pinpoint and disrupt an immunodominant capsid site, significantly dampening immune activation while preserving biodistribution. A clear step toward less immunogenic AAVs and more durable gene therapies. Discover how immuno-engineering is reshaping AAV design: https://lnkd.in/e6iwvDpv